Overall, epigenetic agents, primarily DNMT and HDAC inhibitors, have undergone major preclinical investigations and extensive clinical trials, either alone or in combinations with each other or conventional chemotherapeutic agents, for their efficacy to treat various types of solid cancers, including CRC [118,238]. This evidence concerns the gene DNMT1 and colorectal carcinoma.